Publication:
Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with AQP4+NMOSD: The Phase 3 PREVENT Study

Simple item page
dc.contributor.authorKim, H.
dc.contributor.authorPittock, S.
dc.contributor.authorBerthele, A.
dc.contributor.authorFujihara, K.
dc.contributor.authorLevy, M.
dc.contributor.authorPalace, J.
dc.contributor.authorWingerchuk, D.
dc.date.accessioned2020-06-21T12:18:00Z
dc.date.available2020-06-21T12:18:00Z
dc.date.issued2020
dc.departmentOMÜen_US
dc.department-temp[Kim, H.] Natl Canc Ctr, Res Inst & Hosp, Dept Neurol, Goyang, South Korea -- [Pittock, S.] Mayo Clin, Dept Neurol, Rochester, MN USA -- [Berthele, A.] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, Munich, Germany -- [Fujihara, K. -- Nakashima, I.] Tohoku Univ, Dept Neurol, Sendai, Miyagi, Japan -- [Levy, M.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA -- [Palace, J.] John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford, Englanden_US
dc.descriptionAmericas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum -- FEB 27-29, 2020 -- West Palm Beach, FLen_US
dc.description.abstract…en_US
dc.description.sponsorshipAmericas Comm Treatment & Res Multiple Sclerosisen_US
dc.identifier.endpage105en_US
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.startpage105en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12712/10057
dc.identifier.volume26en_US
dc.identifier.wosWOS:000532412600226
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleImpact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with AQP4+NMOSD: The Phase 3 PREVENT Studyen_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu